279 related articles for article (PubMed ID: 16678350)
21. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation.
Dekker A; Bulley S; Beyene J; Dupuis LL; Doyle JJ; Sung L
J Clin Oncol; 2006 Nov; 24(33):5207-15. PubMed ID: 17114653
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of colony-stimulating factors in acute leukemia.
Holdsworth MT; Mathew P
Ann Pharmacother; 2001 Jan; 35(1):92-108. PubMed ID: 11197591
[TBL] [Abstract][Full Text] [Related]
23. [Hematopoietic growth factors in the prevention of infections complications in children with hematologic-oncologic diseases].
Lehrnbecher T
Klin Padiatr; 2001 Sep; 213 Suppl 1():A88-102. PubMed ID: 11577368
[TBL] [Abstract][Full Text] [Related]
24. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis.
Berghmans T; Paesmans M; Lafitte JJ; Mascaux C; Meert AP; Jacquy C; Burniat A; Steels E; Vallot F; Sculier JP
Support Care Cancer; 2002 Apr; 10(3):181-8. PubMed ID: 11904782
[TBL] [Abstract][Full Text] [Related]
26. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
[TBL] [Abstract][Full Text] [Related]
27. Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children.
Kim H; Mousa SA
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):977-986. PubMed ID: 35929962
[TBL] [Abstract][Full Text] [Related]
28. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
Clark OA; Lyman GH; Castro AA; Clark LG; Djulbegovic B
J Clin Oncol; 2005 Jun; 23(18):4198-214. PubMed ID: 15961767
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
Thomas X; Boiron JM; Huguet F; Reman O; Sutton L; Turlure P; Garban F; Gardin C; Espinouse D; Boulat O; Lhéritier V; Fiere D;
Hematol J; 2004; 5(5):384-94. PubMed ID: 15448664
[TBL] [Abstract][Full Text] [Related]
30. [G-CSF in oncology].
Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
[TBL] [Abstract][Full Text] [Related]
31. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
32. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
33. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
34. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.
Cornes P; Gascon P; Chan S; Hameed K; Mitchell CR; Field P; Latymer M; Arantes LH
Adv Ther; 2018 Nov; 35(11):1816-1829. PubMed ID: 30298233
[TBL] [Abstract][Full Text] [Related]
35. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
Lyman GH
J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
[TBL] [Abstract][Full Text] [Related]
36. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.
Gurion R; Belnik-Plitman Y; Gafter-Gvili A; Paul M; Vidal L; Ben-Bassat I; Shpilberg O; Raanani P
Cochrane Database Syst Rev; 2011 Sep; (9):CD008238. PubMed ID: 21901718
[TBL] [Abstract][Full Text] [Related]
37. The colony-stimulating factors: use to prevent and treat neutropenia and its complications.
Komrokji RS; Lyman GH
Expert Opin Biol Ther; 2004 Dec; 4(12):1897-910. PubMed ID: 15571452
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.
Saloustros E; Tryfonidis K; Georgoulias V
Expert Opin Pharmacother; 2011 Apr; 12(6):851-63. PubMed ID: 21254862
[TBL] [Abstract][Full Text] [Related]
39. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
[TBL] [Abstract][Full Text] [Related]
40. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
Barnes G; Pathak A; Schwartzberg L
Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
